Skip to search formSkip to main contentSkip to account menu

BM 573

Known as: BM-573, BM573 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms.
BACKGROUND Abdominal aortic aneurysm (AAA) is one of the leading causes of death in western countries. Surgery is still, at the… 
2013
2013
Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.
2011
2011
Prostaglandins and Other Lipid Mediators M-573 inhibits the development of early atherosclerotic lesions in Apo E eficient mice by blocking TP receptors and thromboxane synthase
Atherosclerosis is the principal cause of mortality in industrialized countries. Its development is influenced by several… 
2007
2007
Bm-573, an original thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient (apo e-/-) mice
2006
2006
Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents
Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to… 
2004
2004
Effect of BM-573, a dual thromboxane synthase inhibitor and TP receptor antagonist, in a porcine model of acute pulmonary embolism
The aim of this study was to evaluate the effect of BM-573, a dual thromboxane A2 synthase inhibitor and receptor antagonist, on… 
2004
2004
In vivo pharmacological evaluation of BM-573, an original thromboxane A2 receptor antagonist and thromboxane synthase inhibitor
2003
2003
Effects of BM-573, a Novel Thromboxane A2 Inhibitor, on Pulmonary Hemodynamics in Endotoxic Shock
Thromboxane A 2 is considered to be partially responsible for the increase in pulmonary vascular resistance observed after… 
2003
2003
A dual thromboxane inhibitor and thromboxane receptor antagonist prevents pig myocardial infarction induced by coronary thrombosis
2003
2003
Pharmacological evaluation of BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)